AVADEL PHARMACEUTICALS PLC — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2021-02-15

Reporting Person: Kim Richard J (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-15	Stock Option (right to buy)	$8.99	A	350000	Acquired	2031-02-15	ADSs (350000)	Direct

Footnotes

F1: Options become exercisable as to 87,500 ADSs on each of the first four anniversaries after the 02/15/2021 grant date.

F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.